NASDAQ: MIRM

Mirum Pharmaceuticals (MIRM) Stock Analysis & Forecast

Nov 13 close

$93.99+0.66 (+0.7%)

Gekko Brief

AI summaryNov 9 close

Mirum Pharmaceuticals raised its 2026 net product sales guidance to $715 million-$720 million following third-quarter sales of $186 million, building on an earlier raise to $680-$700 million discussed alongside second-quarter results. The company also launched a sponsored genetic testing program with GeneDx for rare liver disease patients, part of its focus on treatments like Livmarli. Analyst activity was mixed in tone: Leerink Partners maintained its Outperform rating while lowering its price target to $140 from $154, and HC Wainwright & Co. maintained its Buy rating while raising its target to $202 from $200. CEO Christopher Peetz sold 20,000 shares at an average price of $90.00, for a total of $1,800,000.00.

MIRM closed at $93.18, down 0.6%, sitting between its 50-day average of $89.20 and 200-day average of $98.53. The GekkoIndex reads 49.5, placing the stock in the Neutral zone. The current price sits 18.5% below Gekko Fair Value of $114.36.

The next earnings date falls on 24 February 2027, 106 days out, beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective 90-day and 30-day windows. Seasonality over the next 20 trading days has averaged -4.5% across 5 years, rising in 2 of those years. Consensus among 12 covering firms stands at a Buy rating with a target of $153.43.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Mirum Pharmaceuticals price vs fair value

$114.27$93.99Nov ’25May ’26Nov ’26
Close $93.99200-day averageGekko Fair Value $114.27

Mirum Pharmaceuticals quick facts

Market cap
$6.14B
P/E ratio
—
Forward P/E
196.1
EPS, TTM
−$14.47
Revenue, TTM
$670.8M
Profit margin
-134.7%
Dividend yield
—
Beta
0.74
Volume
331,048 avg 608,243
1-year return
+32.8%
Typical daily move
±4.4%
Typical 20-day move
±8.7%
50-day average
$88.79
200-day average
$98.41
Next earnings
Feb 24
Shares outstanding
65.28M
52-week range
$63.23$130.00

Mirum Pharmaceuticals swing-trade checklist

Mirum Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $93.99 sits between the 50-day ($88.79) and 200-day ($98.41) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    52, Neutral

    Reading 52 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    17.7% below

    Price is 17.7% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 101 days

    Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −3.8% on average

    From this point in the calendar, the next 20 trading days averaged −3.8% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Mirum Pharmaceuticals stock chart and price history

Mirum Pharmaceuticals closed at $93.99 on Nov 13, 2026, +32.8% over the past year, inside a 52-week range of $63.23 to $130.00.

Close50-day average200-day averageVolume
Mirum Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$60$80$100$120DecJan 2026FebMarAprMayJunJulAugSepOctNov93.99

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+14.1%
3 months
−5.8%
6 months
−8.0%
1 year
+32.8%
The full MIRM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MIRM in Gekko

Follow Mirum Pharmaceuticals through every session

Put MIRM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track MIRM in GekkoFree for 7 days. No credit card required.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals works on medicines meant for patients facing uncommon and severely underserved illnesses, with much of its attention on disorders of the liver. The company is most recognized for LIVMARLI, a treatment taken by mouth that is being tested against progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia.

Alongside this, Mirum is also moving forward with Volixibat, aimed at treating intrahepatic cholestasis that occurs during pregnancy as well as primary sclerosing cholangitis. These two programs make up the main focus of what the company is building toward, as it works to turn early-stage research into approved treatments for people living with these conditions.

Mirum Pharmaceuticals traces its founding to 2018 and keeps its base in Foster City, California. Its stock trades on the NASDAQ exchange under the symbol MIRM.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
mirumpharma.com

Mirum Pharmaceuticals GekkoIndex: the smart money zone

Mirum Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52, in the Neutral zone, up 3 points over five sessions.

010052Neutral

Up 3 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying18−0.3%+1.5%+7.3%+8.6%
Accumulation223+0.9%+2.1%+4.3%+14.0%
Neutral (current zone)391+1.0%+1.9%+4.5%+11.4%
Distribution62+2.4%+3.2%+1.7%+6.5%
Selling8Too few readings yet

Average MIRM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the MIRM price, zone by zone.Track MIRM in Gekko

Is Mirum Pharmaceuticals stock overvalued? Gekko Fair Value

Mirum Pharmaceuticals trades 17.7% below Gekko Fair Value of $114.27, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Mirum Pharmaceuticals shares are worth, recalculated every trading day.

$114.27

Gekko Fair Value, Nov 14, 2026

17.7% Undervalued

At the end of Aug 2026 the price was 23.6% below the estimate.

Gekko Fair ValueShare price, month end
$114$94Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open MIRM in Gekko

Mirum Pharmaceuticals insider and Congress trading

No open-market insider purchases were filed for Mirum Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for MIRM in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every MIRM insider filing, plotted on the chart in Gekko.Open MIRM in Gekko

Congress trades last 90 days

No trades in MIRM were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for MIRM, plotted on the chart in Gekko.Open MIRM in Gekko

Hedge funds and billionaires quarter ended Dec 31

0of the funds Gekko tracks hold MIRM.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Mirum Pharmaceuticals earnings: next date and track record

Mirum Pharmaceuticals reports on Feb 24, 2027 (101 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±8.1%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

+5.6%Nov ’24−5.9%Feb ’25+10.3%May ’25+15.4%Aug ’25−1.1%Nov ’25−14.2%Feb ’26−2.7%May ’26−9.8%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
Mirum reported Q2 2026 net product sales of $176 million, driven by strong portfolio demand. The company raised full-year 2026 net product sales guidance to $680-$700 million. Key pipeline updates include FDA breakthrough therapy designation for volixibat in PSC, though FDA recommended an additional Phase 3 study, delaying NDA submission to H1 2027. FOP drug Zilurgisertib launch is imminent with PDUFA date next month.
Guidance
Full-year 2026 net product sales guidance raised to $680-$700 million. NDA submission for volixibat in PSC now targeted for H1 2027 following FDA feedback. VANTAGE study in PBC completed enrollment with 330+ patients, with Q1 top-line readout expected next year.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026−$1.06
est −$0.74
−42.8%$176.2M
est $166.3M
+5.9%−9.8%
May 6, 2026−$13.43
est −$0.40
−3,257.5%$159.9M
est $148.2M
+7.9%−2.7%
Feb 25, 2026−$0.11
est $0.02
−650.0%$148.9M
est $142.5M
+4.5%−14.2%
Nov 4, 2025$0.05
est −$0.10
+150.0%$133.0M
est $140.9M
−5.6%−1.1%
Aug 6, 2025−$0.12
est −$0.31
+61.3%$127.8M
est $130.1M
−1.8%+15.4%
May 7, 2025−$0.30
est −$0.39
+23.1%$111.6M
est $98.40M
+13.4%+10.3%
Feb 26, 2025−$0.49
est −$0.25
−98.7%$99.41M
est $96.64M
+2.9%−5.9%
Nov 12, 2024−$0.30
est −$0.45
+33.3%$90.38M
est $95.44M
−5.3%+5.6%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Mirum Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Mirum Pharmaceuticals is $154.00, +63.8% from the last close, from 12 firms rating the stock in the last 90 days.

$154.00consensus 12-month target, +63.8% from the last close
Low $130High $202
Buy12
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 12 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 11H.C. WainwrightBuy, reiterated$202+114.9%
Nov 11CitiBuy, maintained$194+106.4%
Nov 9J.P. MorganBuy, maintained——
Nov 9CitiBuy, maintained$184+95.8%
Nov 5Morgan StanleyBuy, reiterated$152+61.7%
+4.5%average 20-day move after past Neutral readings
−3.8%average move over the next 20 trading days in the last 5 years
±4.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Mirum Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Mirum Pharmaceuticals averaged −3.8% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−10.3%2021−6.3%2022+11.8%2023−8.3%2024−10.3%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.0%2 of 5
Next 10 trading days−0.6%2 of 5
Next 15 trading days−2.9%2 of 5
Next 20 trading days−3.8%1 of 5
Next 30 trading days−0.1%2 of 5

For scale, MIRM’s typical 20-trading-day move in either direction is about 8.7%.

Mirum Pharmaceuticals market cap and key statistics

Mirum Pharmaceuticals’s market cap is $6.14B and revenue of $670.8M over the last twelve months.

Valuation

Market cap
$6.14B
Forward P/E
196.1
EPS, TTM
−$14.47
Gekko Fair Value
$114.27

Trading

Volume
331,048
Avg volume, 20 days
608,243
52-week high
$130.00
52-week low
$63.23
Shares outstanding
65.28M

Financials

Revenue, TTM
$670.8M
Profit margin
-134.7%
Return on equity
-760%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.74
Typical daily move
±4.4%
Typical 20-day move
±8.7%

Mirum Pharmaceuticals peers

Mirum Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Mirum Pharmaceuticals stock FAQ

What is Mirum Pharmaceuticals’s market cap?

Mirum Pharmaceuticals’s market cap is $6.14B at the Nov 13, 2026 close of $93.99, with 65.28M shares outstanding.

What is the Mirum Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Mirum Pharmaceuticals is $154.00, +63.8% from the last close. Of the 12 firms that rated the stock in the last 90 days, 12 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Mirum Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Mirum Pharmaceuticals is undervalued: the Nov 13, 2026 close of $93.99 is 17.7% below Gekko Fair Value of $114.27. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Mirum Pharmaceuticals report earnings next?

Mirum Pharmaceuticals is expected to report on Feb 24, 2027 (101 days away). Analysts expect earnings of −$0.62 per share on revenue of $194.5M. Mirum Pharmaceuticals beat the earnings estimate in 4 of its last 8 reports, moving 8.1% on average across the report.

What is Mirum Pharmaceuticals’s 52-week high and low?

Mirum Pharmaceuticals’s 52-week high is $130.00 and its 52-week low is $63.23; it closed at $93.99 on Nov 13, 2026, +32.8% over the past year.

Is Mirum Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 2 as mixed (trend and gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Mirum Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.